Novabay Pharmaceuticals (NBY) 0.99 $NBY
NovaBay Pharmaceuticals Reports Second Quarter 2014 Financial Results and a Clinical/Business Update
Business Wire - Thu Jul 31, 7:05AM CDT
--Advanced i-Lid Cleanser Introduced at the American Society of Cataract and Refractive Surgery in April 2014 with US Commercial Launch Planned for Q3, 2014
In RadioMD Interview, Dr. John Crew Describes Successful New Treatment for Flesh-Eating Disease
PR Newswire - Thu Jul 24, 8:40AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today is calling attention to an interview on RadioMD with Dr. John Crew, Medical Director of the Advanced Wound Care Center at Seton Medical Center in Daly City, California. The subject: A new treatment for deadly flesh-eating disease, or necrotizing fasciitis.
NovaBay Pharmaceuticals Announces Direct US Marketing-Sales Campaign for New i-Lid(TM) Cleanser Product
Business Wire - Wed Jul 16, 7:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infectives, announced today it will initiate a major marketing campaign and commercialization effort for the company's new product, i-Lid(TM) Cleanser. The product launch will be led by Glenn Moro, NovaBay's new Vice President of Sales and Marketing.
Letter to NovaBay Shareholders
Business Wire - Thu Jul 10, 5:37PM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on non-antibiotic anti-infectives, announced today the distribution of a letter from Ron Najafi, the Company's Chairman, Chief Executive Officer, to its stockholders. A downloadable version of this letter may be obtained by visiting the CEO Blog on the NovaBay website (www.novabay.com/blog).
NovaBay's New Product for Serious Eye Conditions Highlighted in CEOLIVE.TV Interview
Business Wire - Thu Jul 03, 7:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on non-antibiotic anti-infectives, announced today that CEOLIVE.TV, an online service that delivers news about companies to investors, has highlighted NovaBay's important advance in eye care through an interview with Kathryn Najafi-Tagol, M.D., the founder and director of the Eye Institute of Marin in San Rafael, California.
British Prime Minister David Cameron Warns of Growing Crisis of Antibiotic-Resistant Bacteria, But Wound Care Expert Dr. John Crew Points to Possible Solution
PR Newswire Europe - Wed Jul 02, 4:06PM CDT
-- A new treatment for life-threatening 'flesh eating' disease pioneered by Dr. John Crew can fight the resistant bacteria that turn scratches into deadly infections
Dr. Christine W. Sindt Will Describe Benefits of NovaBay's i-Lid Cleanser at American Optometric Association Meeting
Business Wire - Thu Jun 26, 7:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company, announced today that Christine Sindt OD, Clinical Associate Professor of Ophthalmology and Visual Sciences at University of Iowa's Carver College of Medicine, will describe the benefits of treating common eye and eyelid conditions using NovaBay's new i-Lid(TM) Cleanser on June 27, 2014 during the annual Optometry's Meeting(R) of the American Optometric Association in Philadelphia, PA. NovaBay representatives will be available at the AOA Meeting in Booth #1615 to meet with eye care professionals interested in learning more about i-Lid Cleanser and placing orders for product to be shipped to their practice.
Ophthalmology Times Highlights the Benefits of New i-Lid(TM) Cleanser
Business Wire - Tue Jun 17, 7:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company, announced today that an article in Ophthalmology Times has highlighted the "novel advances" provided by NovaBay's new i-Lid Cleanser. The product, said the June 1 article, is "a safe and effective alternative for cleansing the lids, lashes, and periocular skin of debris and microorganisms, which can cause irritation, inflammation, and ocular surface disease."
New i-Lid(TM) Cleanser Effectively Treats Common Eye Problems in Elderly, Says Phoenix Optometrist
PR Newswire - Wed Jun 11, 5:39PM CDT
Dr. Arthur Epstein, Director of the Dry Eye - Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care, announced in a recent webinar that the elderly now have a potent new solution for eye problems such as inflammation of the eyelids associated with blepharitis and dry eye syndrome. These eye conditions are especially common in Arizona because of the large number of retirees and the desert climate, said Dr. Epstein.
New i-Lid(TM) Cleanser Effectively Treats Common Eye Problems in Elderly, Says Phoenix Ophthalmologist
PR Newswire - Wed Jun 11, 8:01AM CDT
Dr. Arthur Epstein, Director of the Dry Eye - Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care, announced in a recent webinar that the elderly now have a potent new solution for eye problems such as inflammation of the eyelids associated with blepharitis and dry eye syndrome. These eye conditions are especially common in Arizona because of the large number of retirees and the desert climate, said Dr. Epstein.
NovaBay Pharmaceuticals Announces Presentation of Positive Data From Its Clinical Trial of Auriclosene Irrigation Solution for Urinary Catheter Encrustation and Blockage
Business Wire - Tue May 20, 10:29AM CDT
--Investigational Catheter Irrigation Solution Shows Promise in Improving the Quality of Life for Patients with Long-Term Indwelling Catheters
NovaBay Catheter Solution Product Shows Promise in Stopping Bacteria Blockages In Urinary Catheters, Says Urologist Dr. Linsenmeyer of the Kessler Institute
ACCESSWIRE - Tue Apr 01, 7:25AM CDT
In a Stock Sector interview, Dr. Todd Linsenmeyer describes the problem of encrustation and blockage of urinary catheters—and how NovaBay's auriclosene product can reduce the problem, thus improving patients' quality of life and reducing health care costs
Triple Amputation From Flesh-Eating Disease in the United Kingdom Highlights Importance of NovaBay's NeutroPhase Wound Cleanser
Business Wire - Fri Mar 28, 3:42PM CDT
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY). The Daily Mirror, a British newspaper, recently reported the tragic story of a father who lost both legs, an arm and half of his face to deadly flesh-eating bacteria. Alex Lewis, 34, went to bed with what he thought was a common cold, but had to be rushed to the hospital hours later in toxic shock. Doctors were barely able to save his life--and the treatment required three emergency amputations.
NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Mar 20, 10:01AM CDT
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it has priced an underwritten public offering of an aggregate of 5,600,000 shares of its Common Stock, and 18-month warrants to purchase up to an aggregate of 1,400,000 shares of Common Stock at a combined price to the public of $1.20 for aggregate gross proceeds of $6,720,000. The shares of common stock and warrants will be issued separately. The warrants are exercisable immediately upon issuance, have an 18-month term and an exercise price of $1.56 per share. The warrants will be certificated, and will be delivered to the investors by physical delivery following the closing. There is no established public trading market for the warrants and NovaBay does not expect a market to develop in the future. The offering is expected to close on or about March 25, 2014, subject to customary closing conditions.
NovaBay Pharmaceuticals to launch public offering of common stock and warrants
M2 - Thu Mar 20, 6:37AM CDT
Biopharmaceutical company NovaBay Pharmaceuticals (NYSE MKT:NBY) said on Wednesday that it plans to issue common stock and warrants in a public offering.
NovaBay Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Mar 19, 3:32PM CDT
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it intends to offer shares of its common stock and warrants in an underwritten public offering. The company intends to use the net proceeds from this offering for working capital and general corporate purposes, including research and development, clinical trials and selling, general and administrative expenses. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
NovaBay Pharmaceuticals' (NYSE MKT:NBY) Thomas Paulson Interviewed by Mike Elliott of CEOLIVE.TV -- Video Posted on InvestmentPitch.com
Thomson Reuters ONE - Tue Mar 18, 10:01AM CDT
Vancouver, BC, March 18, 2014 - CEOLIVE.TV's Mike Elliott interviews NovaBay Pharmaceuticals' (NYSE MKT:NBY) Thomas Paulson CFO. There is a growing, worldwide crisis of germ resistance to antibiotics. NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the large unmet therapeutic needs of the global, topical anti-infective market.
NovaBay Pharmaceuticals Reports Fourth Quarter 2013 and 2013 Year End Financial Results and Provides a Clinical/Business Update
GlobeNewswire - Fri Mar 07, 7:30AM CST
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing non-antibiotic, topical anti-microbial products, today reported fourth quarter 2013 and fiscal year 2013 financial results and provided a clinical and business update.
NovaBay CEO Comments on President Obama's 'Superbug' Budget Initiative and Reports by the CDC on Antibiotic Resistance
GlobeNewswire - Fri Mar 07, 2:59AM CST
A recent journal article by NovaBay researchers describes the growing threat of resistance - and how the nation can fight it
NovaBay Pharmaceuticals Reports Second Quarter 2014 Financial Results and a Clinical/Business Update
Business Wire - Thu Jul 31, 7:05AM CDT
--Advanced i-Lid Cleanser Introduced at the American Society of Cataract and Refractive Surgery in April 2014 with US Commercial Launch Planned for Q3, 2014
In RadioMD Interview, Dr. John Crew Describes Successful New Treatment for Flesh-Eating Disease
PR Newswire - Thu Jul 24, 8:40AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today is calling attention to an interview on RadioMD with Dr. John Crew, Medical Director of the Advanced Wound Care Center at Seton Medical Center in Daly City, California. The subject: A new treatment for deadly flesh-eating disease, or necrotizing fasciitis.
NovaBay Pharmaceuticals Announces Direct US Marketing-Sales Campaign for New i-Lid(TM) Cleanser Product
Business Wire - Wed Jul 16, 7:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infectives, announced today it will initiate a major marketing campaign and commercialization effort for the company's new product, i-Lid(TM) Cleanser. The product launch will be led by Glenn Moro, NovaBay's new Vice President of Sales and Marketing.
Letter to NovaBay Shareholders
Business Wire - Thu Jul 10, 5:37PM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on non-antibiotic anti-infectives, announced today the distribution of a letter from Ron Najafi, the Company's Chairman, Chief Executive Officer, to its stockholders. A downloadable version of this letter may be obtained by visiting the CEO Blog on the NovaBay website (www.novabay.com/blog).
NovaBay's New Product for Serious Eye Conditions Highlighted in CEOLIVE.TV Interview
Business Wire - Thu Jul 03, 7:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on non-antibiotic anti-infectives, announced today that CEOLIVE.TV, an online service that delivers news about companies to investors, has highlighted NovaBay's important advance in eye care through an interview with Kathryn Najafi-Tagol, M.D., the founder and director of the Eye Institute of Marin in San Rafael, California.
British Prime Minister David Cameron Warns of Growing Crisis of Antibiotic-Resistant Bacteria, But Wound Care Expert Dr. John Crew Points to Possible Solution
PR Newswire Europe - Wed Jul 02, 4:06PM CDT
-- A new treatment for life-threatening 'flesh eating' disease pioneered by Dr. John Crew can fight the resistant bacteria that turn scratches into deadly infections
Dr. Christine W. Sindt Will Describe Benefits of NovaBay's i-Lid Cleanser at American Optometric Association Meeting
Business Wire - Thu Jun 26, 7:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company, announced today that Christine Sindt OD, Clinical Associate Professor of Ophthalmology and Visual Sciences at University of Iowa's Carver College of Medicine, will describe the benefits of treating common eye and eyelid conditions using NovaBay's new i-Lid(TM) Cleanser on June 27, 2014 during the annual Optometry's Meeting(R) of the American Optometric Association in Philadelphia, PA. NovaBay representatives will be available at the AOA Meeting in Booth #1615 to meet with eye care professionals interested in learning more about i-Lid Cleanser and placing orders for product to be shipped to their practice.
Ophthalmology Times Highlights the Benefits of New i-Lid(TM) Cleanser
Business Wire - Tue Jun 17, 7:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company, announced today that an article in Ophthalmology Times has highlighted the "novel advances" provided by NovaBay's new i-Lid Cleanser. The product, said the June 1 article, is "a safe and effective alternative for cleansing the lids, lashes, and periocular skin of debris and microorganisms, which can cause irritation, inflammation, and ocular surface disease."
New i-Lid(TM) Cleanser Effectively Treats Common Eye Problems in Elderly, Says Phoenix Optometrist
PR Newswire - Wed Jun 11, 5:39PM CDT
Dr. Arthur Epstein, Director of the Dry Eye - Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care, announced in a recent webinar that the elderly now have a potent new solution for eye problems such as inflammation of the eyelids associated with blepharitis and dry eye syndrome. These eye conditions are especially common in Arizona because of the large number of retirees and the desert climate, said Dr. Epstein.
New i-Lid(TM) Cleanser Effectively Treats Common Eye Problems in Elderly, Says Phoenix Ophthalmologist
PR Newswire - Wed Jun 11, 8:01AM CDT
Dr. Arthur Epstein, Director of the Dry Eye - Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care, announced in a recent webinar that the elderly now have a potent new solution for eye problems such as inflammation of the eyelids associated with blepharitis and dry eye syndrome. These eye conditions are especially common in Arizona because of the large number of retirees and the desert climate, said Dr. Epstein.
NovaBay Pharmaceuticals Announces Presentation of Positive Data From Its Clinical Trial of Auriclosene Irrigation Solution for Urinary Catheter Encrustation and Blockage
Business Wire - Tue May 20, 10:29AM CDT
--Investigational Catheter Irrigation Solution Shows Promise in Improving the Quality of Life for Patients with Long-Term Indwelling Catheters
NovaBay Catheter Solution Product Shows Promise in Stopping Bacteria Blockages In Urinary Catheters, Says Urologist Dr. Linsenmeyer of the Kessler Institute
ACCESSWIRE - Tue Apr 01, 7:25AM CDT
In a Stock Sector interview, Dr. Todd Linsenmeyer describes the problem of encrustation and blockage of urinary catheters—and how NovaBay's auriclosene product can reduce the problem, thus improving patients' quality of life and reducing health care costs
Triple Amputation From Flesh-Eating Disease in the United Kingdom Highlights Importance of NovaBay's NeutroPhase Wound Cleanser
Business Wire - Fri Mar 28, 3:42PM CDT
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY). The Daily Mirror, a British newspaper, recently reported the tragic story of a father who lost both legs, an arm and half of his face to deadly flesh-eating bacteria. Alex Lewis, 34, went to bed with what he thought was a common cold, but had to be rushed to the hospital hours later in toxic shock. Doctors were barely able to save his life--and the treatment required three emergency amputations.
NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Mar 20, 10:01AM CDT
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it has priced an underwritten public offering of an aggregate of 5,600,000 shares of its Common Stock, and 18-month warrants to purchase up to an aggregate of 1,400,000 shares of Common Stock at a combined price to the public of $1.20 for aggregate gross proceeds of $6,720,000. The shares of common stock and warrants will be issued separately. The warrants are exercisable immediately upon issuance, have an 18-month term and an exercise price of $1.56 per share. The warrants will be certificated, and will be delivered to the investors by physical delivery following the closing. There is no established public trading market for the warrants and NovaBay does not expect a market to develop in the future. The offering is expected to close on or about March 25, 2014, subject to customary closing conditions.
NovaBay Pharmaceuticals to launch public offering of common stock and warrants
M2 - Thu Mar 20, 6:37AM CDT
Biopharmaceutical company NovaBay Pharmaceuticals (NYSE MKT:NBY) said on Wednesday that it plans to issue common stock and warrants in a public offering.
NovaBay Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Mar 19, 3:32PM CDT
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it intends to offer shares of its common stock and warrants in an underwritten public offering. The company intends to use the net proceeds from this offering for working capital and general corporate purposes, including research and development, clinical trials and selling, general and administrative expenses. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
NovaBay Pharmaceuticals' (NYSE MKT:NBY) Thomas Paulson Interviewed by Mike Elliott of CEOLIVE.TV -- Video Posted on InvestmentPitch.com
Thomson Reuters ONE - Tue Mar 18, 10:01AM CDT
Vancouver, BC, March 18, 2014 - CEOLIVE.TV's Mike Elliott interviews NovaBay Pharmaceuticals' (NYSE MKT:NBY) Thomas Paulson CFO. There is a growing, worldwide crisis of germ resistance to antibiotics. NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the large unmet therapeutic needs of the global, topical anti-infective market.
NovaBay Pharmaceuticals Reports Fourth Quarter 2013 and 2013 Year End Financial Results and Provides a Clinical/Business Update
GlobeNewswire - Fri Mar 07, 7:30AM CST
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing non-antibiotic, topical anti-microbial products, today reported fourth quarter 2013 and fiscal year 2013 financial results and provided a clinical and business update.
NovaBay CEO Comments on President Obama's 'Superbug' Budget Initiative and Reports by the CDC on Antibiotic Resistance
GlobeNewswire - Fri Mar 07, 2:59AM CST
A recent journal article by NovaBay researchers describes the growing threat of resistance - and how the nation can fight it
